Glucagon-like Peptide 1 Global Market Report 2024

The glucagon-such as peptide 1 market has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $21.01 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%.The increase in the historical period can be attributed to the growing incidence of diabetes, emphasis on enhanced diabetes management, patient inclination toward injectable therapies, clinical effectiveness, safety profiles, and advancements in diabetes research.

The glucagon-such as peptide 1 market is expected to see strong growth in the next few years. It will grow to $28.17 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The expansion expected in the forecast period can be attributed to the rise of oral GLP-1 therapies, a focus on personalized medicine, integration into diabetes treatment algorithms, and patient-centric approaches in healthcare. Major trends in the forecast period include market growth in emerging economies, regulatory approvals for new formulations, emphasis on personalized medicine, patient education and awareness programs, and dynamics in the competitive landscape.

The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.

The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.

Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.

Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, made a strategic acquisition of Protomer Technologies for approximately $1 billion. This acquisition positions Eli Lilly to leverage Protomer's next-generation protein therapeutics, particularly in the development of therapeutic peptides and proteins for individuals with diabetes. Protomer Technologies, a biotechnology company based in the US, specializes in protein therapeutics, including the creation of glucose-responsive insulin for diabetes therapy.

Major companies operating in the glucagon-such as peptide 1 market report are Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd., Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd., Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc., ConjuChem Biotechnologies, MannKind Corporation,, Provention Bio Inc., Regeneron Pharmaceuticals.

North America was the largest region in the glucagon-such as peptide 1 market in 2023. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.

The glucagon-such as peptide 1 market research report provides glucagon-such as peptide 1 market statistics, including glucagon-such as peptide 1 industry global market size, regional shares, competitors with a glucagon-such as peptide 1 market share, detailed glucagon-such as peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-such as peptide 1 industry. This glucagon-such as peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.